牛牛AI助理已提取核心訊息
On March 6, 2024, Avenue Therapeutics, Inc. announced that a majority of its capital stock's voting power approved a discretionary grant to its board of directors to effectuate a reverse stock split. The approved range for the reverse stock split is between 30-for-1 and 75-for-1, with the board authorized to determine the exact ratio. The decision was made through a written consent signed by holders of 3,133,886 shares of common stock and 250,000 shares of Class A Preferred Stock. This represents approximately 56% of the voting power as of the consent date. The board also approved the reverse stock split and will file an amendment to the company's Third Amended and Restated Certificate of Incorporation with the Delaware Secretary of State. A Schedule 14C information statement will be filed with the SEC and provided to the company's stockholders.
On March 6, 2024, Avenue Therapeutics, Inc. announced that a majority of its capital stock's voting power approved a discretionary grant to its board of directors to effectuate a reverse stock split. The approved range for the reverse stock split is between 30-for-1 and 75-for-1, with the board authorized to determine the exact ratio. The decision was made through a written consent signed by holders of 3,133,886 shares of common stock and 250,000 shares of Class A Preferred Stock. This represents approximately 56% of the voting power as of the consent date. The board also approved the reverse stock split and will file an amendment to the company's Third Amended and Restated Certificate of Incorporation with the Delaware Secretary of State. A Schedule 14C information statement will be filed with the SEC and provided to the company's stockholders.
2024 年 3 月 6 日，Avenue Therapeutics, Inc. 宣佈，其大部分股本的投票權批准了向其董事會提供全權授權，以實現反向股票分割。反向股票拆分的批准範圍在30比1和75比1之間，董事會有權確定確切的比率。該決定是通過3,133,886股普通股和25萬股A類優先股的持有人簽署的書面同意書做出的。截至同意之日，這約佔投票權的56％。董事會還批准了反向股票拆分，並將向特拉華州國務卿提交對公司第三次修訂和重述的公司註冊證書的修正案。附表14C信息聲明將提交給美國證券交易委員會，並提供給公司的股東。
2024 年 3 月 6 日，Avenue Therapeutics, Inc. 宣佈，其大部分股本的投票權批准了向其董事會提供全權授權，以實現反向股票分割。反向股票拆分的批准範圍在30比1和75比1之間，董事會有權確定確切的比率。該決定是通過3,133,886股普通股和25萬股A類優先股的持有人簽署的書面同意書做出的。截至同意之日，這約佔投票權的56％。董事會還批准了反向股票拆分，並將向特拉華州國務卿提交對公司第三次修訂和重述的公司註冊證書的修正案。附表14C信息聲明將提交給美國證券交易委員會，並提供給公司的股東。
有用
沒用